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The lymphatic vascular system plays important roles in
the maintenance of tissue fluid homeostasis, in the media-
tion of the afferent immune response, and in the metastatic
spread of malignant tumors to regional lymph nodes. It
consists of a dense network of blind ending, thin-walled
lymphatic capillaries and collecting lymphatics that drain
extravasated protein-rich fluid from most organs and trans-
port the lymph via the thoracic duct to the venous circula-
tion (1). Originally discovered as “milky veins” by Gasparo
Aselli in the 17th century (2), the mechanisms controlling
the normal development of lymphatic vessels and the mo-
lecular regulation of their biological function have re-
mained poorly understood in contrast to the rapid progress
made in elucidating the formation and molecular control of
the blood vascular system (3, 4).
100 yr ago, Florence Sabin proposed that the lymphatic
system develops by the sprouting of endothelial cells from
embryonic veins, leading to the formation of primitive
lymph sacs from which lymphatic endothelial cells then
sprout into surrounding organs to form mature lymphatic
networks (5, 6). Since these pioneering studies, however,
the field of lymphatic research has remained rather ne-
glected, mainly due to the lack of molecular tools to specif-
 
ically detect and functionally characterize the lymphatic
endothelium. The recent identification of several new
markers for lymphatic endothelial cells and of lymphatic
growth factors and receptors, together with the character-
ization of genetic mouse models with impaired lymphatic
development and/or function, has now led to a “rediscov-
ery” of the lymphatic vascular system and has provided im-
portant new insights into the molecular mechanisms that
control its development and biological function (7). Impor-
tantly, these studies have largely confirmed Sabin’s original
 
hypothesis regarding lymphatic development in the mamma-
lian system (Fig. 1).
Recently, Wigle and Oliver (8) and Wigle et al. (9) have
identified the first gene that is essential for early lymphatic
development. Beginning at E9.5 of mouse development,
the homeobox gene Prox1 starts to become specifically ex-
pressed in a subpopulation of endothelial cells located on
one side of the anterior cardinal vein (8). At this stage, the
venous endothelium also expresses the hyaluronan receptor
LYVE-1, a CD44 homologue (10), and vascular endothe-
lial cell growth factor receptor (VEGFR)-3, a receptor for
the lymphangiogenesis factors vascular endothelial growth
factor (VEGF)-C and VEGF-D (11). The expression of
both of these receptors later becomes restricted to lym-
phatic endothelium (Fig. 1; reference 12). This is followed
 
by the polarized budding and migration of Prox1
 
  
 
lym-
phatic endothelial progenitor cells (8) that progressively
down-regulate the expression of blood vascular genes, such
as CD34 and laminin (9), and express increasing levels of
lymphatic markers such as VEGFR-3 and secondary lym-
phoid chemokine (CCL21), a ligand for the chemokine re-
ceptor CCR7 (13). Importantly, in Prox1 null mice, the
budding and sprouting of lymphatic endothelial cells from
the veins is arrested around E11.5-E12.0 and they com-
pletely lack a lymphatic vascular system (8). With the re-
ported haploinsufficiency effect of Prox1 during the devel-
opment of the enteric lymphatic system, these findings
reveal an essential role of Prox1 during early lymphatic
specification and development (8, 9). The exact mecha-
nisms of action of Prox1 during and after the switch from
the blood vascular to the lymphatic phenotype remain to
be identified. However, recent studies revealed that ectopi-
cal expression of Prox1 in primary human blood vascular
 
endothelial cells was sufficient to up-regulate the expression
of the lymphatic endothelial cell markers podoplanin and
VEGFR-3, and repress the expression of several genes that
have been associated with the blood vascular endothelial
cell phenotype (14). These results identify Prox1 as a mas-
ter control gene in the program specifying lymphatic endo-
thelial cell fate (14).
Recent studies in angiopoietin-2–deficient mice suggest
an important role of the angiopoietins and their receptor
Tie2 for the final developmental steps of lymphatic net-
work patterning (Fig. 1) and lymphatic vessel maturation
(14). However, the molecular mechanisms controlling the
sprouting of lymphatic endothelial cells from primitive
lymph sacs and their migration into adjacent organs and
tissues (lymphangiogenesis) have remained unclear. In this
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issue, Saaristo et al. (15) identify VEGF-C as a potent in-
ducer of lymphatic sprouting and provide experimental ev-
idence that in addition to VEGFR-3, VEGFR-2 may also
be required for this process. Previously, the authors had
shown that signaling via VEGFR-3 was sufficient to induce
hyperplasia of cutaneous lymphatic vessels because trans-
genic mice with skin-specific overexpression of a mutated
VEGF-C (K14-VEGF-C156S) that selectively activates
VEGFR-3 developed lymphatic vessel enlargement in the
skin (17). In contrast, wild-type VEGF-C activates both
VEGFR-3 and, after proteolytic processing, VEGFR-2.
In the study by Saaristo et al., K14-VEGF-C or K14-
VEGF-C156S transgenic mice were crossed with VEGFR-
3
 
 
 
/LacZ mice in which one allele of VEGFR-3 had been
replaced by the LacZ gene, thereby enabling the visualiza-
tion of lymphatic vessels by X-gal staining. Importantly,
whereas VEGF-C156S overexpression mainly caused the
enlargement of preexisting lymphatic capillaries, wild-type
VEGF-C induced lymphatic vessel sprouting during em-
bryogenesis (16). Similarly, an increased number of cutane-
ous lymphatic vessels was detected in adult VEGF-C trans-
genic mice and in adult mice that were intradermally
injected with an adenovirus encoding VEGF-C, whereas
chronic transgenic delivery of VEGF-C156S or intradermal
injection of a VEGF-C156S–encoding adenovirus pre-
dominantly induced lymphatic enlargement. Moreover,
only VEGF-C but not VEGF-C156S also induced angio-
genesis and vascular hyperpermeability in these studies,
most likely via interaction with VEGFR-2 on blood vascu-
lar endothelium. These results indicate that VEGF-C,
through interaction with both VEGFR-3 and VEGFR-2,
plays an important role in lymphangiogenesis, i.e., the
sprouting of lymphatics from preexisting vessels. This is
similar to the effects of VEGF-A in angiogenesis where it
induces sprouting of new blood vessels (18, 19). Future
studies in mice deficient for VEGF-C or VEGF-D, a re-
lated lymphangiogenesis factor with comparable VEGFR
binding properties, should reveal whether the activation of
VEGFR-3 and VEGFR-2 is only sufficient, as shown here,
or also necessary for the induction of lymphangiogenesis
during normal embryonic development. Moreover, addi-
tional studies are needed to investigate whether or not
mesenchymal lymphatic progenitor cells might contribute
to embryonic (or postnatal) lymphangiogenesis, as has been
recently proposed for the early wing bud development in
birds (20).
In addition to providing new insights into the mecha-
nisms directing lymphatic development, this study by
Saaristo et al. raises new questions regarding the molecular
control of angiogenesis versus lymphangiogenesis. In this
study, VEGFR-2 was implicated in the induction of lym-
phatic sprouting and strong expression of VEGFR-2 was
detected on collecting lymphatic vessels. Therefore, one
might expect that VEGF, thus far thought to specifically
induce blood vascular angiogenesis (21), might also be able
to activate lymphatic vessel sprouting via the activation of
VEGFR-2. Indeed, VEGFR-2 is expressed by cultured
lymphatic endothelial cells (22, 23) and VEGF equally
stimulates lymphatic and blood vascular endothelial growth
in vitro (23 and unpublished data). Moreover, intradermal
injection of a VEGF165-encoding adenovirus into mouse
ears resulting in high levels of VEGF expression, potently
induced the formation of new lymphatic vessels that per-
sisted for up to 1 yr (Dvorak, H.F., personal communica-
tion). In contrast, cutaneous wound healing is associated
with up-regulated expression of VEGF (24) and the forma-
tion of a richly vascularized granulation tissue that initially
contains no or only a few lymphatic vessels (unpublished
data). Is the formation of VEGFR-3 and VEGFR-2 het-
erodimers needed for the efficient formation of lymphatic
vessel sprouts, as suggested by Saaristo et al. (16)? Does
VEGF need simultaneous activation/binding of VEGFR-1,
most likely not expressed by lymphatic endothelium in
vivo (unpublished data) but by cultured lymphatic endo-
thelial cells (22), and of VEGFR-2 to exert its angiogenic
effects under pathological conditions, as suggested by re-
cent findings in placenta growth factor–deficient mice (21)?
Does VEGF, via its vascular permeability–inducing activity,
create a tissue environment that is permissive for blood vas-
cular endothelial proliferation and sprouting, but not for
lymphangiogenesis despite the activation of VEGFR-2,
possibly due to the differential expression of extracellular
matrix receptors by lymphatic endothelium? Do the ob-
Figure 1. Hypothetical model of the distinct steps involved in the em-
bryonic development of the mammalian lymphatic vasculature. 
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served effects of adenoviral VEGF expression on lymphan-
giogenesis represent a physiological response of lymphatic
endothelium to increased tissue fluid accumulation, or are
they caused by the induction of VEGF-C expression in
vascular endothelium as has been reported (25)? Future in
vivo and in vitro studies, including gene expression profil-
ing, are needed to address this unresolved discrepancy.
Impaired formation of lymphatic vessels results in insuffi-
cient fluid drainage from tissues, leading to chronic
lymphedema that is characterized by edematous swelling of
the skin, epithelial hyperplasia, dermal fibrosis, delayed tis-
sue repair, and impaired immune response (1). Recently,
missense mutations in the VEGFR-3 gene have been de-
tected in some cases of primary congenital lymphedema
(Milroy disease), indicating an important role of VEGF-C
and/or VEGF-D in the normal development of the human
lymphatic system (26). Consequently, a heterozygous inac-
tivating VEGFR-3 mutation was identified in 
 
Chy
 
 mutant
mice that develop cutaneous lymphedema and chylous as-
cites after birth and may serve as a convenient mouse
model for primary lymphedema (27). Importantly, virus-
mediated VEGF-C gene therapy stimulated the growth of
functional lymphatics in this model (27), indicating the po-
tential applicability of growth factor gene therapy to at least
some cases of human lymphedema. However, adenoviral
VEGF-C gene therapy also induced blood vascular en-
largement and increased vascular permeability via interac-
tion with VEGFR-2, unwanted side effects in the context
of clinical antilymphedema therapy (28). Saaristo et al. (16)
now provide evidence that these blood vascular side effects
were avoided by viral gene transfer of a VEGFR-3–specific
mutant form of VEGF-C (VEGF-C156S) to wild-type and
 
Chy
 
 lymphedema mice. Remarkably, the authors detected
functional cutaneous lymphatic vessels as confirmed by
their ability to transport intradermally injected FITC-dex-
tran even 8 mo after the injection of the VEGF-C156S-
adeno–associated virus into the ear skin of 
 
Chy
 
 mutant mice,
whereas no changes of blood vascularity were observed.
These findings have potential implications for the devel-
opment of novel therapies for human lymphedema, and it
will be of interest to see whether the intradermal injection
of naked VEGF-C156S plasmid cDNA, as previously de-
scribed for VEGF treatment of peripheral artery disease
(29), or of recombinant VEGF-C156S protein will also be
able to specifically induce the formation of functional lym-
phatics, avoiding potential side effects associated with the in
vivo application of adenoviral constructs. However, one
has to keep in mind that thus far missense mutations of
VEGFR-3 have only been detected in a minority of all pa-
tients with congenital lymphedema and additional gene
mutations are likely responsible for the majority of these
cases. The recent identification of inactivating mutations of
the FOXC2 gene in the autosomal-dominant disorder
lymphedema-distichiasis (30), together with the detection
of lymphedema, chylous ascites, or chylothorax in an in-
creasing number of mutant mouse models such as 
 
 
 
9 inte-
grin and angiopoietin-2–deficient mice (15, 31), and the
identification of novel lymphatic-specific markers such as
Prox1, LYVE-1, and podoplanin (32), suggests the pres-
ence of additional disease-specific targets for the future
treatment of primary lymphedemas.
Secondary lymphedema is frequently induced by the sur-
gical removal or radiation of lymph nodes in cancer pa-
tients, whereas filariasis, a chronic infection with the para-
sitic worms 
 
Brugia malayi
 
 or 
 
Wuchereria bancrofti
 
, is the
leading cause in the developing world. Secondary lymph-
edema after surgery is associated with the interruption of
the normal lymphatic drainage system. Recent studies in an
experimental postsurgery lymphedema model, involving
the removal of lymphatic vessels from rabbit ears, showed
that the injection of VEGF-C protein into the wounded
area induced the growth of functional lymphatics along
with normalization of the tissue structure (33). Therefore,
postsurgical lymphedemas might constitute additional tar-
gets for VEGF-C– or VEGF-C165S–based protein or gene
therapies. The recent discovery of a direct correlation be-
tween experimental tumor-associated lymphangiogenesis
and enhanced lymph node metastasis (34–37), however,
suggests that future studies are warranted to evaluate
whether therapeutic regeneration of lymphatic vessels after
lymph node removal might increase the risk for enhanced
spread of tumor metastases.
Tumor metastasis to regional lymph nodes represents the
first step of tumor dissemination in many common human
cancers and serves as a major prognostic indicator for the
progression of the disease. In contrast to the extensive mo-
lecular and functional characterization of tumor angiogene-
sis (38), i.e., the induction of new blood vessel growth, lit-
tle is known about the mechanisms through which tumor
cells gain entry into the lymphatic system. A widely held
view has suggested that lymphatic endothelium only plays a
passive role during this process (38) and lymphatic invasion
only occurs once stroma-infiltrating tumor cells happen
upon preexisting peritumoral lymphatic vessels (Fig. 2 A).
However, the recent identification of lymphatic growth
factors and receptors, together with the discovery of lym-
phatic-specific markers and the development of orthotopic
cancer metastasis models, have provided important new in-
sights into the formation of tumor-associated lymphatic
vessels (7) and their active contribution to lymphatic tumor
spread (Fig. 2 B). An increasing number of clinicopatho-
logical studies have shown a direct correlation between tu-
mor expression of the lymphangiogenesis factors VEGF-C
or VEGF-D and metastatic tumor spread in many human
cancers, including cancers of the breast, lung, prostate, cer-
vix, and colon (for review see reference 39), providing cir-
cumstantial evidence for the involvement of lymphangio-
genesis in tumor progression.
Several studies in animal tumor models have now pro-
vided direct experimental evidence that increased levels of
VEGF-C or VEGF-D promote tumor lymphangiogenesis
and lymphatic tumor spread to regional lymph nodes and
that these effects can be suppressed by blocking VEGFR-3
signaling (34–37, 40–42). Most of these studies used an an-
tibody against the hyaluronan receptor LYVE-1, a lym-
phatic-specific CD44 homologue (10, 43), to identify and 
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quantify tumor-associated lymphatic vessels. Although
some LYVE-1 expression has been detected in liver sinusoi-
dal endothelial cells that are involved in hyaluronan uptake
(44), recent studies applying the combined immunostains
of a variety of experimental tumors with antibodies to
LYVE-1 and the lymphatic-specific transcription factor
Prox1 found that all LYVE-1
 
  
 
tumor-associated lymphatic
vessels also expressed Prox1 (7, 9, 45), confirming the spec-
ificity of LYVE-1 expression for lymphatic endothelium.
Despite the accumulated evidence for an active role of
VEGF-C– or VEGF-D–induced tumor lymphangiogenesis
in cancer metastasis to regional lymph nodes, the existence
and biological function of lymphatics within experimental
and human tumors has remained controversial. High inter-
stitial pressure within tumors has been proposed to prevent
intratumoral lymphatic vessel growth and function as as-
sessed by the lack of lymphatic uptake of tracers that were
injected in the vicinity of experimental tumors (46, 47).
However, the mechanisms controlling metastatic tumor cell
invasion and transport within lymphatic vessels are most
likely distinct from those involved in fluid uptake and trans-
port. Indeed, proliferating intratumoral lymphatic vessels
have been detected in rapidly progressing tumor xenotrans-
plants and in slowly growing, chemically induced orthoto-
pic squamous cell carcinomas in mice and is associated with
lymphatic metastasis (7, 9, 34, 45). Proliferating intratu-
moral lymphatics have also been found in human head and
neck squamous cell carcinomas that were characterized by
the correlation of the density of LYVE-1
 
  
 
tumor-associated
lymphatic vessels with the presence of regional lymph node
metastasis (48). In contrast, no evidence for tumor lymph-
 
angiogenesis was found in invasive breast cancer by the
same group of investigators (49). Taken together, these re-
sults indicate that active tumor-associated lymphangiogene-
sis induced by VEGF-C, VEGF-D, or other not yet
identified growth factors leads to the proliferation and en-
largement of peritumoral and, in some cancers, intratu-
moral lymphatic vessels, likely enhancing the metastatic
spread of many different types of human tumors (Fig. 2 B).
Although the mere increase of lymphatic vessel surface
area might simply increase the chance for tumor cell inva-
sion and metastasis, lymphatic endothelial cells probably
also play an active role in the chemotactic recruitment and
intralymphatic transport of tumor cells. Lymphatic endo-
thelium secretes chemokines such as CCL21 (secondary
lymphoid chemokine) that binds to CCR7 (13, 22, 50),
leading to chemoattraction and migration of mature den-
dritic cells from the skin to regional lymph nodes. CCR7
and other chemokine receptors are also expressed by some
human cancer cell lines including malignant melanomas
and breast cancer cells (51). Importantly, the overexpres-
sion of CCR7 in B16 malignant melanoma cells led to a
 
 
 
10-fold increase in the incidence of regional lymph
node metastases after injection into the footpad of mice,
and treatment with CCL21-blocking antibodies com-
pletely prevented metastatic tumor spread to lymph nodes
(52). These findings indicate that some tumors might take
advantage of preexisting molecular mechanisms designed
for the physiological immune response to further their
metastatic spread.
After several decades of slow progress, the study of lym-
phatic vessel formation and its role in malignant disease has
Figure 2. (A) Traditional model of tumor metastasis via lymphatic and blood vessels. (B) Active lymphangiogenesis model of tumor metastasis. 
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now led to the identification of several molecular mecha-
nisms involved in the formation and biological function of
lymphatic vessels. Although much has still to be learned
about the detailed steps of normal and pathological lymph
vessel formation, new targets for innovative therapeutic ap-
proaches and new tools for the prognostic evaluation of
human cancers are now emerging.
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